NanoViricides, Inc. (NNVC) Revenue, Earnings & Financial Statements
$1.17ASE: NNVCMarket Cap $29.87M
Data as of Nov 17, 2026 (intraday, delayed) · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)
NanoViricides, Inc. most recently reported annual revenue of $0, a net loss of $8.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
NanoViricides, Inc.: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of $8.0M.
Income Statement — 10 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$10.0M
$9.0M
$9.0M
$8.0M
$9.0M
$8.0M
$9.0M
$9.0M
$10.0M
$8.0M
Operating Profit
−$10.0M
−$9.0M
−$9.0M
−$8.0M
−$9.0M
−$8.0M
−$9.0M
−$9.0M
−$10.0M
−$8.0M
Other Income
−$1.0M
$1.0M
$0
−$5.0M
$0
$0
$0
$0
$0
$0
Interest
$2.0M
$1.0M
$0
$0
$0
$0
$0
$0
$0
$0
Depreciation
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
Profit Before Tax
−$10.0M
−$9.0M
−$8.0M
−$13.0M
−$9.0M
−$8.0M
−$9.0M
−$8.0M
−$9.0M
−$8.0M
Tax rate (%)
0.0%
0.0%
2.1%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$10.0M
−$9.0M
−$8.0M
−$13.0M
−$9.0M
−$8.0M
−$9.0M
−$8.0M
−$9.0M
−$8.0M
EPS
−$3.43
−$2.64
−$2.30
−$2.39
−$0.81
−$0.70
−$0.74
−$0.70
−$0.63
−$0.41
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$2.0M
$2.0M
$2.0M
$2.0M
$3.0M
$2.0M
$2.0M
$2.0M
$2.0M
$2.0M
$2.0M
$2.0M
Operating Profit
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$3.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$3.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$3.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
EPS
−$0.17
−$0.18
−$0.16
−$0.20
−$0.23
−$0.14
−$0.14
−$0.13
−$0.10
−$0.11
−$0.09
−$0.11
Over the 10 years reported for NanoViricides, Inc., borrowings decreased from $4.0M in 2017 to $0 in 2026, cash stood at $3.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 3.00 times.
Balance Sheet — 10 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total Assets
$27.0M
$19.0M
$13.0M
$24.0M
$30.0M
$23.0M
$17.0M
$13.0M
$9.0M
$10.0M
Current Assets
$15.0M
$7.0M
$3.0M
$14.0M
$21.0M
$14.0M
$8.0M
$5.0M
$2.0M
$3.0M
Cash
$15.0M
$7.0M
$3.0M
$14.0M
$21.0M
$14.0M
$8.0M
$5.0M
$2.0M
$3.0M
Inventory
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Receivables
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Fixed Assets
$11.0M
$11.0M
$10.0M
$10.0M
$9.0M
$9.0M
$8.0M
$8.0M
$7.0M
$6.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Other Assets
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$7.0M
$1.0M
$3.0M
$2.0M
$0
$0
$2.0M
$1.0M
$1.0M
$1.0M
Current Liabilities
$5.0M
$1.0M
$3.0M
$2.0M
$0
$0
$1.0M
$1.0M
$1.0M
$1.0M
Borrowings
$4.0M
$0
$0
$1.0M
$0
$0
$0
$0
$0
$0
Other Liabilities
$3.0M
$1.0M
$3.0M
$1.0M
$0
$0
$2.0M
$1.0M
$1.0M
$1.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
$20.0M
$18.0M
$11.0M
$22.0M
$30.0M
$23.0M
$15.0M
$11.0M
$8.0M
$9.0M
For NanoViricides, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $7.78T; free cash flow was positive in 0 of 10 years.
Cash Flow Statement — 10 Years (USD millions)
Metric
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Operating Cash Flow
−$8.0M
−$8.0M
−$7.0M
−$7.0M
−$8.0M
−$6.0M
−$6.0M
−$6.0M
−$8.0M
−$7.70T
Investing Cash Flow
$0
$0
$0
$0
$0
−$1.0M
$0
$0
$0
−$168.6B
Financing Cash Flow
$0
−$5.0M
$0
$0
$0
$0
$0
$0
$0
$9.02T
Net Cash Flow
−$9.0M
−$8.0M
−$5.0M
$11.0M
$7.0M
−$6.0M
−$6.0M
−$3.0M
−$3.0M
$1.24T
Free Cash Flow
−$8.0M
−$8.0M
−$7.0M
−$7.0M
−$8.0M
−$6.0M
−$6.0M
−$6.0M
−$9.0M
−$7.78T
Valuation & Return Ratios
Metric
Value
PEG Ratio
-0.07
EV / EBITDA
-4.37
FCF Yield
8766261.02%
Quick Ratio
2.66
Interest Coverage
—
Return 1Y
-8.89%
Return 3Y
-8.21%
Return 5Y
-70.45%
NanoViricides, Inc. (NNVC) financials — frequently asked questions
What is NanoViricides, Inc.'s annual revenue?
NanoViricides, Inc. (NNVC) reported annual revenue of $0 in its most recent fiscal year.
What is NanoViricides, Inc.'s net profit?
NanoViricides, Inc. (NNVC) reported a net loss of $8.0M in its most recent fiscal year.
What is NNVC EV/EBITDA?
NanoViricides, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -4.37. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks